【レポートの概要（一部）】
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 17
2 Introduction 18
2.1 Acquired Gene or Chromosome Alterations Overview 18
3 Products under Development 19
3.1 Acquired Gene or Chromosome Alterations – Pipeline Products by Stage of Development 19
3.2 Acquired Gene or Chromosome Alterations – Pipeline Products by Territory 20
3.3 Acquired Gene or Chromosome Alterations – Pipeline Products by Regulatory Path 21
3.4 Acquired Gene or Chromosome Alterations – Pipeline Products by Estimated Approval Date 22
4 Acquired Gene or Chromosome Alterations – Pipeline Products under Development by Companies 23
4.1 Acquired Gene or Chromosome Alterations Companies – Pipeline Products by Stage of Development 23
4.2 Acquired Gene or Chromosome Alterations – Pipeline Products by Stage of Development 26
5 Acquired Gene or Chromosome Alterations Companies and Product Overview 36
5.1 Abbott Diagnostics Company Overview 36
5.1.1 Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 36
5.2 Agendia NV Company Overview 177
5.2.1 Agendia NV Pipeline Products & Ongoing Clinical Trials Overview 177
5.3 AltheaDx, Inc. Company Overview 178
5.3.1 AltheaDx, Inc. Pipeline Products & Ongoing Clinical Trials Overview 178
5.4 Amarantus Bioscience Holdings, Inc. Company Overview 181
5.4.1 Amarantus Bioscience Holdings, Inc. Pipeline Products & Ongoing Clinical Trials Overview 181
5.5 AstraZeneca Plc Company Overview 183
5.5.1 AstraZeneca Plc Pipeline Products & Ongoing Clinical Trials Overview 183
5.6 AutoGenomics, Inc. Company Overview 185
5.6.1 AutoGenomics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 185
5.7 Biocept, Inc. Company Overview 186
5.7.1 Biocept, Inc. Pipeline Products & Ongoing Clinical Trials Overview 186
5.8 Cepheid Company Overview 189
5.8.1 Cepheid Pipeline Products & Ongoing Clinical Trials Overview 189
5.9 Chinese University of Hong Kong Company Overview 192
5.9.1 Chinese University of Hong Kong Pipeline Products & Ongoing Clinical Trials Overview 192
5.10 Columbia University Company Overview 194
5.10.1 Columbia University Pipeline Products & Ongoing Clinical Trials Overview 194
5.11 Dana-Farber Cancer Institute, Inc. Company Overview 195
5.11.1 Dana-Farber Cancer Institute, Inc. Pipeline Products & Ongoing Clinical Trials Overview 195
5.12 DiaCarta Company Overview 196
5.12.1 DiaCarta Pipeline Products & Ongoing Clinical Trials Overview 196
5.13 Exosome Diagnostics, Inc. Company Overview 197
5.13.1 Exosome Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 197
5.14 Gencurix Co., Ltd. Company Overview 198
5.14.1 Gencurix Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview 198
5.15 GeneFirst Ltd Company Overview 199
5.15.1 GeneFirst Ltd Pipeline Products & Ongoing Clinical Trials Overview 199
5.16 GenMark Diagnostics, Inc. Company Overview 203
5.16.1 GenMark Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 203
5.17 Genomic Health, Inc. Company Overview 205
5.17.1 Genomic Health, Inc. Pipeline Products & Ongoing Clinical Trials Overview 205
5.18 Genomic Vision Company Overview 207
5.18.1 Genomic Vision Pipeline Products & Ongoing Clinical Trials Overview 207
5.19 GenomicTree, Inc. Company Overview 210
5.19.1 GenomicTree, Inc. Pipeline Products & Ongoing Clinical Trials Overview 210
5.20 German Cancer Research Center Company Overview 212
5.20.1 German Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 212
5.21 H. Lee Moffitt Cancer Center & Research Institute, Inc. Company Overview 214
5.21.1 H. Lee Moffitt Cancer Center & Research Institute, Inc. Pipeline Products & Ongoing Clinical Trials Overview 214
5.22 Harvard University Company Overview 216
5.22.1 Harvard University Pipeline Products & Ongoing Clinical Trials Overview 216
5.23 Helmholtz Centre for Infection Research Company Overview 217
5.23.1 Helmholtz Centre for Infection Research Pipeline Products & Ongoing Clinical Trials Overview 217
5.24 HistoRx, Inc. (Inactive) Company Overview 218
5.24.1 HistoRx, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 218
5.25 Illumina, Inc. Company Overview 220
5.25.1 Illumina, Inc. Pipeline Products & Ongoing Clinical Trials Overview 220
5.26 Insight Genetics, Inc. Company Overview 223
5.26.1 Insight Genetics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 223
5.27 InVivoScribe Technologies, Inc. Company Overview 225
5.27.1 InVivoScribe Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview 225
5.28 Med BioGene Inc. Company Overview 226
5.28.1 Med BioGene Inc. Pipeline Products & Ongoing Clinical Trials Overview 226
5.29 Merrimack Pharmaceuticals, Inc. Company Overview 227
5.29.1 Merrimack Pharmaceuticals, Inc. Pipeline Products & Ongoing Clinical Trials Overview 227
5.30 MolecularMD, Corp. Company Overview 229
5.30.1 MolecularMD, Corp. Pipeline Products & Ongoing Clinical Trials Overview 229
5.31 Multiplicom N.V. Company Overview 230
5.31.1 Multiplicom N.V. Pipeline Products & Ongoing Clinical Trials Overview 230
5.32 Myriad Genetics, Inc. Company Overview 231
5.32.1 Myriad Genetics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 231
5.33 Nanosphere, Inc. Company Overview 234
5.33.1 Nanosphere, Inc. Pipeline Products & Ongoing Clinical Trials Overview 234
5.34 New York University Company Overview 237
5.34.1 New York University Pipeline Products & Ongoing Clinical Trials Overview 237
5.35 NIH Office of Technology Transfer Company Overview 238
5.35.1 NIH Office of Technology Transfer Pipeline Products & Ongoing Clinical Trials Overview 238
5.36 Oryzon Genomics S.A. Company Overview 240
5.36.1 Oryzon Genomics S.A. Pipeline Products & Ongoing Clinical Trials Overview 240
5.37 Oxford Biodynamics Limited Company Overview 241
5.37.1 Oxford Biodynamics Limited Pipeline Products & Ongoing Clinical Trials Overview 241
5.38 Panagene Inc. Company Overview 246
5.38.1 Panagene Inc. Pipeline Products & Ongoing Clinical Trials Overview 246
5.39 Pangaea Biotech, S.L. Company Overview 250
5.39.1 Pangaea Biotech, S.L. Pipeline Products & Ongoing Clinical Trials Overview 250
5.40 PDI, lnc. Company Overview 254
5.40.1 PDI, lnc. Pipeline Products & Ongoing Clinical Trials Overview 254
5.41 PharmaSeq, Inc. Company Overview 256
5.41.1 PharmaSeq, Inc. Pipeline Products & Ongoing Clinical Trials Overview 256
5.42 Qiagen N.V. Company Overview 258
5.42.1 Qiagen N.V. Pipeline Products & Ongoing Clinical Trials Overview 258
5.43 RedPath Integrated Pathology, Inc. Company Overview 268
5.43.1 RedPath Integrated Pathology, Inc. Pipeline Products & Ongoing Clinical Trials Overview 268
5.44 Response Genetics, Inc. Company Overview 269
5.44.1 Response Genetics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 269
5.45 Rheonix, Inc. Company Overview 272
5.45.1 Rheonix, Inc. Pipeline Products & Ongoing Clinical Trials Overview 272
5.46 Seegene, Inc. Company Overview 274
5.46.1 Seegene, Inc. Pipeline Products & Ongoing Clinical Trials Overview 274
5.47 Shuwen Biotech Co. Ltd. Company Overview 276
5.47.1 Shuwen Biotech Co. Ltd. Pipeline Products & Ongoing Clinical Trials Overview 276
5.48 Syamala Srinivasa Life Sciences Pvt. Ltd Company Overview 284
5.48.1 Syamala Srinivasa Life Sciences Pvt. Ltd Pipeline Products & Ongoing Clinical Trials Overview 284
5.49 Sygnis AG Company Overview 288
5.49.1 Sygnis AG Pipeline Products & Ongoing Clinical Trials Overview 288
5.50 Sysmex Corporation Company Overview 290
5.50.1 Sysmex Corporation Pipeline Products & Ongoing Clinical Trials Overview 290
5.51 The Johns Hopkins University Company Overview 292
5.51.1 The Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 292
5.52 thromboDx Company Overview 294
5.52.1 thromboDx Pipeline Products & Ongoing Clinical Trials Overview 294
5.53 Transbiomed, SL Company Overview 296
5.53.1 Transbiomed, SL Pipeline Products & Ongoing Clinical Trials Overview 296
5.54 Transgenomic, Inc. Company Overview 297
5.54.1 Transgenomic, Inc. Pipeline Products & Ongoing Clinical Trials Overview 297
5.55 TrovaGene, Inc. Company Overview 299
5.55.1 TrovaGene, Inc. Pipeline Products & Ongoing Clinical Trials Overview 299
5.56 University of California, Irvine Company Overview 301
5.56.1 University of California, Irvine Pipeline Products & Ongoing Clinical Trials Overview 301
5.57 Vela Diagnostics Company Overview 302
5.57.1 Vela Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 302
5.58 Xiamen Zeesan Biotech Co.,Ltd Company Overview 307
5.58.1 Xiamen Zeesan Biotech Co.,Ltd Pipeline Products & Ongoing Clinical Trials Overview 307
6 Acquired Gene or Chromosome Alterations- Recent Developments 311
7 Appendix 345
7.1 Methodology 345
7.2 About GlobalData 347
7.3 Contact Us 348
7.4 Disclaimer 348
【レポート販売概要】
■ タイトル：世界における後天的遺伝子変異または後天的染色体変異検査製品のパイプライン動向2015■ 英文：Acquired Gene or Chromosome Alterations - Pipeline Review, 2015
■ 発行日：2015年10月1日
■ 調査会社：GlobalData
■ 商品コード：GDME0077EPD
■ 調査対象地域：グローバル
- Exillon Energy Plc：石油・ガスの開発・生産動向及びコスト分析- 2012Exillon Energy Plc Oil & Gas Exploration and Production Operations and Cost Analysis - 2012 Summary Exillon Energy Plc Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for key o …
- 世界の合成ゼオライト市場2015The Global Synthetic Zeolites Industry 2015 Market Research Report is a professional and in-depth study on the current state of the Synthetic Zeolites industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Synthetic Zeolites market analysis is provided for the international markets including development t …
- 世界の化学気相成長(CVD)市場動向（2014～2018）TechNavio's analysts forecast the Global Chemical Vapor Deposition market to grow at a CAGR of 11.43 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing demand for CVD in the Semiconductor industry. The Global Chemical Vapor Deposition market has also been witnessing the increasing use of plasma-enhanced CVD. However, the high total cost o …
- 世界のデータセンターネットワーク装備市場：Global Data Center Network Equipment Market 2014-2018TechNavio's analysts forecast the Global Data Center Network Equipment market to grow at a CAGR of 11.97 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing deployment of data centers. The Global Data Center Network Equipment market has also been witnessing the increasing virtualization in network environments. However, the growing complex …
- 種子処理の世界市場2016-2020About Seed Treatment Seed treatment involves the use of processes and products for effective integrated pest management (IPM). It is a sustainable agricultural practice as the use of these products and processes targets the diseases and pests with lower dosages of active ingredients per hectare. Farmers struggle in controlling certain early season soil-borne pests and seed-borne diseases when they …
- 世界のポータブル軍用電子製品市場動向2013-2023：トレンド、開発動向及び課題Technological Developments in the global Man-Portable Military Electronics include: ■ Britain’s new initiative in 2013 to develop man-portable 3G communications base has been successful and might soon be replicated by other armies. ■ Solar portable UAVs ■ EARS Gunshot Localization System
- 世界の塩水脱塩市場動向（2012-2016）TechNavio's analysts forecast the Global Water Desalination market to grow at a CAGR of 9.51 percent over the period 2012-2016. One of the key factors contributing to this market growth is the need for safe water. The Global Water Desalination market has also been witnessing increased governmental initiatives in the Water industry. However, the possibility of water desalination putting the ocean e …
- フレーバー粉末飲料の世界市場2017-2021About Flavored Powder Drinks There are many drivers contributing to the growth of the global flavored powder drinks market. The primary factor contributing to the growth of the market is the increasing awareness about the health benefits of flavored powder drinks. The growth in the organized retail also increases the product availability for the consumers, which will, in turn, drive the market. Te …
- LTE・5Gブロードキャストの世界市場展望2017-2026According to Stratistics MRC, the Global LTE and 5G Broadcast Market is accounted for $371.89 million in 2017 and is expected to reach $1,099.50 million by 2026 growing at a CAGR of 12.8% during the forecast period. Factors such as increasing LTE mobile subscribers and penetration of smartphones and need of minimizing network capacity congestion are fuelling the market growth. However, reluctance …
- 地盤計測・モニタリングの世界市場予測（～2024年）“GTIM market to grow at significant rate from 2019 to 2024” The geotechnical instrumentation and monitoring (GTIM) market is expected to grow from USD 3.3 billion in 2019 to USD 5.0 billion by 2024, growing at a CAGR of 9.0%. Key factors driving the growth of the GTIM market include a significant rise in infrastructure investments across various countries; stringent government regulations to make …
- 冷凍療法の世界市場分析：治療別（凍結手術、アイスパック療法、チャンバー療法）、装置別（クライオガン、クライオプローブ、ガスシリンダー、クライオチェンバー、ガス圧力計、熱電対装置）、用途別（腫瘍学、心臓学、皮膚科、疼痛管理、眼科、婦人科）、セグメント予測The global cryotherapy market was valued at USD 2.5 billion in 2015 and is expected to reach a value of USD 5.6 billion by 2024. This growth is majorly attributed to the rising demand for minimally invasive procedures and the surging prevalence of skin, retinoblastoma, prostate, and cervical cancer, and others. Minimally invasive cryosurgery provides various advantages over conventional surgery su …
- 前立腺肥大症（BPH）治療薬の世界市場ABSTRACTAbout Benign Prostatic Hyperplasia Drugs Urology is a branch of medicine that deals with the health of the urinary tract and reproductive tract in men and women. Urologic diseases or conditions include infection in the urinary tract, bladder control problems, kidney stones and prostate problems, among others. The prostate gland surrounds the urethra, the tube that carries urine from the bl …
- 自立式遊具の世界市場2017-2021ABSTRACTAbout Freestanding Playground Equipment Freestanding playground equipment refers to commercial playground equipment that is available at schools, playschools, and parks. Slides, swings, and climbers, are the most common types of freestanding playground equipment. Others such as seesaws, spring riders, and rope courses are also popular. Freestanding playground equipment refers to commercial …
- Haywood Electric Membership Corporation：発電所及びSWOT分析2013Haywood Electric Membership Corporation - Power Plants and SWOT Analysis, 2013 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executives), and major products and services. Scope - Major Power Plants (asse …
- 世界の貼合せ用接着剤市場予測：溶剤型接着剤、無溶媒接着剤、水性接着剤The report covers the global laminating adhesive market. It divides the market on the basis of applications and regions. The market data for these types is given with respect to volume (Kilotons) and value ($Million). The market value of laminating adhesive was estimated to be $1,357 million in 2013 and is projected to grow with a CAGR of about 8.8% between 2014 and 2019. The data mentioned in the …
